London and New York, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes the recent movement in its share price and, notwithstanding the recent share price increase of its Partner Companies Motif Bio plc
London and New York, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes the recent movement in its share price and, notwithstanding the recent share price increase of its Partner Companies Motif Bio plc (“Motif”), in which the Company has a holding of approximately 8.5 per cent. and Polarean Imaging Plc in which the Company has a holding of approximately 18.2 per cent., confirms that it is not aware of any specific reason for this movement.
The Company remains cash constrained and as previously announced continues to consider both its short term and medium-term funding options and work with the Company’s debt providers, including the Convertible Promissory Note (“CPN”) holders with whom the Company has been able to reach accommodations in the past. The Company is proposing to extend the term of the debt to 31 December 2019 following expiration of the CPN on 31 December 2018. A further announcement will be made in this regard in due course.
For further information please contact:
| Amphion Innovations | Tel: +1 (212) 210 6224 | ||||
| Charlie Morgan | |||||
| Panmure Gordon Limited (Nominated Adviser and Corporate Broker) | Tel: +44 (0)20 7886 2500 | ||||
| Emma Earl/ Freddy Crossley (Corporate Finance) | |||||
| Charles Leigh-Pemberton (Corporate Broking) | |||||
| SP Angel Corporate Finance LLP (Joint Corporate Broker) | Tel: +44 20 3470 0470 | ||||
| David Hignell (Corporate Finance) | |||||
| Vadim Alexandre (Corporate Broking) | |||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com | ||||
| Anna Dunphy / Paul McManus | |||||
